ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System

Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced the issuance of European Patent No. 3730041, which protects its Thermo Acoustic Enhanced UltraSound (TAEUS®) system. This breakthrough technology enables the calculation of fat concentration in the human body using thermoacoustic measurements. ENDRA's portfolio now includes 54 patents worldwide, with eight issued in Europe. The company aims to develop hybrid ultrasound and thermoacoustic imaging systems to address unmet clinical needs, particularly for Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Positive

• Issuance of European Patent No. 3730041 protecting TAEUS® technology.
• Increased intellectual property portfolio now totaling 54 patents globally.
• Potential market expansion for TAEUS® in addressing NAFLD and NASH.

Negative

• None.

ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.” The ‘041 patent protects ENDRA's TAEUS system for the calculation of fat concentration in the human body with multiple thermoacoustic measurements. The ‘041 patent is related to U.S. patent 9980677B1 and Chinese patent ZL201880050042.2.

“We are pleased to be issued this latest patent in Europe to support our strategy to develop optimized hybrid ultrasound and thermoacoustic imaging systems and to broaden the potential applications for our proprietary TAEUS^® technology in areas with unmet clinical needs,” stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently features 54 patents issued globally, including eight issued in Europe.”

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50^th the cost and at the point of patient care. TAEUS^® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Forward-Looking Statements

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” "anticipate," “attempt,” "believe," "could," "estimate," "expect," “forecast,” “future,” "goal," “hope,” "intend," "may," "plan," “possible,” “potential,” “project,” "seek," "should," "will," “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA's business strategy; ENDRA’s ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; and ENDRA’s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220819005324/en/

Irina Pestrikova

Senior Director, Finance

investors@endrainc.com

www.endrainc.com



Investor Relations:

Yvonne Briggs

LHA Investor Relations

(310) 691-7100

YBriggs@lhai.com

Source: ENDRA Life Sciences Inc.

FAQ

What is the significance of ENDRA's European Patent No. 3730041 for NDRA?

The patent protects ENDRA's TAEUS® technology, enhancing its market position and intellectual property portfolio.

How many patents does ENDRA Life Sciences currently hold?

ENDRA now holds 54 patents worldwide, including eight in Europe.

What clinical applications does ENDRA's TAEUS® technology target?

TAEUS® aims to measure liver fat for diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

How does TAEUS® compare to traditional imaging technologies?

TAEUS® offers a cost-effective solution at 1/50th the cost of MRI, designed for use at the point of patient care.